## Linax

### Linagliptin

#### COMPOSITION

Linax Tablet: Each film coated tablet contains Linagliptin INN 5 mg.

### DESCRIPTION

Linagliptin is an inhibitor of DPP-4, an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Thus, linagliptin increases the concentrations of active incretin hormones, stimulating the release of insulin in a glucose-dependent manner and decreasing the levels of glucagon in the circulation. Both incretin hormones are involved in the physiological regulation of glucose homeostasis. Incretin hormones are secreted at a low basal level throughout the day and levels rise immediately after meal intake. GLP-1 and GIP increase insulin biosynthesis and secretion from pancreatic beta-cells in the presence of normal and elevated blood glucose levels, Furthermore, GLP-1 also reduces glucagon secretion from pancreatic alphacells, resulting in a reduction in hepatic glucose output.

### **INDICATION**

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

### DOSAGE AND ADMINISTRATION

The recommended dose of Linagliptin is 5 mg once daily. Linagliptin tablets can be taken with or without food. Renal or hepatic impairment: No dose adjustment required.

### CONTRAINDICATION

Linagliptin is contraindicated in patients with a history of a hypersensitivity reaction to linagliptin, such as urticaria, angioedema, or bronchial hyperreactivity.

### **PRECAUTION**

When used with an Insulin secretagogue (e.g., sulfonylurea) or Insulin, consider lowering the dose of the Insulin secretagogue or Insulin to reduce the risk of hypoglycemia. If pancreatitis is suspected, Linagliptin should be discontinued. There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with Linagliptin or any other antidiabetic drug.

# SIDE EFFECT

Some of the less common side effects are nasopharyngitis, hypoglycemia.

### **USE IN PREGNANCY AND LACTATION**

Pregnancy: There are no adequate and well-controlled studies in pregnant women. Linagliptin tablets should be used during pregnancy only if the potential benefit of mother justifies the potential risk of the fetus.

**Nursing mothers:** Caution should be exercised when Linagliptin is administered to a nursing woman.

**Pediatric patients:** Safety and effectiveness of Linagliptin in patients below the age of 18 have not been established.

### USE IN GERIATRIC PATIENT

No adjustment of dosage is required in the elderly.

# **STORAGE**

**Linax** should be stored between 15°C to 30° C.

### PRESENTATION:

**Linax** Tablet: Each box contains 60 tablets in blister pack.

# Manufactured by:



The IBN SINA Pharmaceutical Industry Ltd. IBN SINA Shafipur, Kliakoir, Gazipur, Bangladesh.